Januvia Shortage: What Providers and Prescribers Need to Know in 2026

As a prescriber managing patients with type 2 diabetes, you've likely fielded questions about Januvia (sitagliptin) access. While Januvia is not formally listed in the FDA Drug Shortage Database as of 2026, its brand-name-only status and high retail cost create meaningful access challenges that affect adherence and glycemic outcomes. This briefing covers current supply status, cost and coverage landscape, patient assistance options, prescribing alternatives, and what's ahead on the generic horizon.

Current Supply Status

Januvia is NOT on the FDA Drug Shortage Database as of 2026. Merck & Co. manufactures sitagliptin in 25 mg, 50 mg, and 100 mg tablets and maintains adequate distribution to major pharmacy chains. In 2022, nitrosamine impurity (NTTP) concerns triggered quality reviews and regional availability disruptions, but those issues have been resolved. Current Januvia inventory meets FDA quality and safety standards.

Smaller independent pharmacies may not routinely stock Januvia due to its high acquisition cost and lower turnover compared to generic alternatives. If patients report difficulty locating Januvia, directing them to large chain pharmacies or using a pharmacy-location service like medfinder for Providers can expedite access.

Cost and Coverage Landscape

The average retail price for Januvia 100 mg (30 tablets) is approximately $600–$700. No true generic of Januvia (sitagliptin phosphate) is yet widely available, though:

Zituvio (sitagliptin free base, Zydus) — FDA-approved October 2023. Contains sitagliptin in a different chemical form; not automatically substitutable for Januvia; requires a separate prescription. Available at select pharmacies for ~$80–$110/month.

Generic sitagliptin phosphate — Patent expires November 24, 2026. Settlement agreements may allow generic entry as early as May 2026. When available, expected cost reduction of 80–85%.

For insured patients, Januvia is typically placed on Tier 2–3 formulary. Many plans require prior authorization, step therapy (failure of metformin first), or have quantity limits. Medicare Part D patients face additional complexity, particularly those in the coverage gap.

Patient Assistance and Savings Programs

Familiarity with these programs allows you to proactively address cost barriers at the point of prescribing:

Merck Savings Card: Eligible commercially insured patients pay as little as $5/prescription, saving up to $150 per fill (up to a 90-day supply per fill). Not valid for patients with Medicaid, Medicare, or other government insurance. Card available at januvia.com.

Merck Patient Assistance Program (merckhelps.com): Provides Januvia free of charge for uninsured and underinsured patients who meet income requirements. Patients can reapply annually. Contact: 1-800-727-5400.

GoodRx / SingleCare discount cards: Can reduce Januvia's out-of-pocket price to $285–$350 at participating pharmacies; GoodRx shows generic sitagliptin (Zituvio/authorized generic) as low as $110. May be useful for patients not eligible for manufacturer programs.

Merck sample program: Practitioners can request samples through the Merck Sample Portal to bridge gaps while patients navigate insurance approvals or assistance programs.

Prior Authorization Strategy

If your patient requires a prior authorization for Januvia, the following documentation supports a strong PA request:

Documentation of metformin use/intolerance (most PAs require this as step 1)

Current HbA1c level and goal

Renal function (eGFR) — relevant for dose adjustment and clinical rationale

Clinical rationale for DPP-4 inhibitor class specifically (e.g., low hypoglycemia risk, weight neutrality, tolerability)

If applicable: contraindications to alternative agents (e.g., heart failure history precluding sulfonylureas or saxagliptin)

Therapeutic Alternatives When Januvia Is Not Accessible

When Januvia is unavailable or cost-prohibitive, consider these alternatives based on patient-specific factors:

Tradjenta (linagliptin): DPP-4 inhibitor; primarily biliary elimination — ideal for moderate-severe CKD (no dose adjustment); neutral cardiovascular profile; brand-name only but manufacturer savings programs available

Generic saxagliptin (formerly Onglyza): DPP-4 inhibitor; lower cost as generic; avoid in patients with HF risk (SAVOR-TIMI 53 signal)

Generic alogliptin (formerly Nesina): DPP-4 inhibitor; low cost as generic; similar HF warning to saxagliptin

Zituvio (sitagliptin free base): Same active ingredient as Januvia; ~$80–$110/month at select pharmacies; requires separate Rx

SGLT2 inhibitors (empagliflozin, dapagliflozin): If patient has established ASCVD, HF, or CKD with albuminuria, ADA guidelines prioritize SGLT2 inhibitors over DPP-4 inhibitors regardless of Januvia access issues

Formulary Planning: Generic Sitagliptin on the Horizon

As you and your patients approach the second half of 2026, keep in mind that generic sitagliptin phosphate may begin entering the market. Once available, formulary tiers will likely shift to Tier 1 or 2, prior authorization requirements may be lifted, and price will fall dramatically. If you have patients currently on step therapy or PA denials for Januvia, check back with their insurance plan later in 2026 as the generic landscape shifts.

How medfinder for Providers Can Help

When patients can't fill their Januvia prescription, the process of locating a pharmacy with stock often falls on your staff — wasting valuable clinical time. medfinder for Providers helps your team quickly identify which pharmacies near your patient can fill their prescription, so you can focus on clinical care rather than pharmacy logistics.

Share the patient-facing version of this article with your patients: Januvia Shortage Update: What Patients Need to Know in 2026.